AMPH — Amphastar Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapContrarian

Annual income statement for Amphastar Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	438	499	644	732	720
Cost of Revenue
Gross Profit	200	249	354	374	356
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	354	397	450	527	579
Operating Profit	83.5	102	194	205	140
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	84.1	116	171	190	124
Provision for Income Taxes
Net Income After Taxes	63.5	92.6	140	160	98.1
Minority Interest
Equity in Affiliates
Net Income Before Extraordinary Items
Net Income	62.1	91.4	138	160	98.1
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	62.1	91.4	138	160	98.1
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.04	1.83	2.68	3.06	2.03